疯狂做受xxxx高潮不断,亚洲中文无码永久免弗,亚洲免费视频免在线观看,国产老妇伦国产熟女老妇高清

  1. 首頁(yè)
  2. 資源與支持
  3. 歷年文獻(xiàn)

歷年文獻(xiàn)

歷年文獻(xiàn)

miR-590-3p Overexpression Improves the Efficacy of hiPSC-CMs for Myocardial?Repair

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：JACC-Basic to Translational Science

Mid1 promotes synovitis in rheumatoid arthritis via ubiquitin-dependent post-translational modification

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：PHARMACOLOGICAL RESEARCH

RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：Journal for ImmunoTherapy of Cancer

Glutathione-depleting Liposome Adjuvant for Augmenting the Efficacy of a Glutathione Covalent Inhibitor Oridonin for Acute Myeloid Leukemia Therapy

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：JOURNAL OF NANOBIOTECHNOLOGY

iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：MedComm

Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：Cell Reports Medicine

Restoring T and B cell generation in X-linked severe combined immunodeficiency mice through hematopoietic stem cells adenine base editing

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：MOLECULAR THERAPY

Integrated multi-omics reveal gut microbiota-mediated bile acid metabolism alteration regulating immunotherapy responses to anti-α4β7-integrin in Crohn’s disease

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：Gut Microbes

HDAC6-dependent deacetylation of NGF dictates its ubiquitination and maintains primordial follicle dormancy

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：Theranostics

Foretinib is effective in acute myeloid leukemia by inhibiting FLT3 and overcoming secondary mutations that drive resistance to quizartinib and gilteritinib

模式生物：小鼠 產(chǎn)品與服務(wù)：- 研究領(lǐng)域：

發(fā)表日期：2024 | 來源雜志：CANCER RESEARCH

微信咨詢 qrcode 請(qǐng)撥打 400 728 0660 在線咨詢 回到頂部